Project Grant HT94252310466
Award Date
7/1/23
Completion Date
6/30/25
Dollars Obligated
$583K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,498,368.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate molecular mechanisms of tumor-immune dynamics and evolution in response to radiation therapy for high- and very high-risk prostate cancer. The award, effective August 1, 2024 through July 31, 2027, will support cutting-edge...
The Defense Health Agency awarded a $168,000 Project Grant to the Massachusetts General Hospital, a division of Partners Healthcare System Incorporated, to support research on carbonizing proton beam therapy for lung cancer. The grant was awarded on January 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) to transform health care for service members and the public through innovative medical research solutions for battlefield injuries and investigations into...
The Defense Health Agency awarded a $1,621,712 Project Grant to The General Hospital Corporation's Research Management Division, operating as Massachusetts General Hospital (MGH), for the "THERAPEUTIC TARGETING OF CHEMORESISTANT RHABDOMYOSARCOMA" project. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research initiatives to improve health outcomes for military service members, veterans, and the...
The U.S. Defense Health Agency awarded a $653,928 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a 3-year research project titled "TARGETING DENDRITIC CELLS IN BLADDER CANCER IMMUNOTHERAPY". The grant, funded under the Military Medical Research and Development program (CFDA 12.420), will support MGH's biomedical research, including clinical trials and laboratory studies, to develop new treatments and diagnostics for...
The Defense Health Agency awarded a $168,200 Project Grant to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development program (CFDA 12.420) to investigate alternative polyadenylation as a mediator of therapeutic resistance in lung cancer. The two-year award beginning July 1, 2021 will support research into innovative medical solutions for lung cancer treatment through the study of alternative polyadenylation, a novel area of investigation that could help...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Massachusetts General Hospital will receive $826,584 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research into the mechanisms mediating the immune response after proton versus photon radiotherapy in IDH-mutant liver cancer. The study aims to investigate medical solutions for the battlefield and transform health care for service members and the public through innovative...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,328,936 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 3-year research project titled "Elucidating Tumor Intrinsic and Extrinsic Drivers of Mucosal Melanoma". The grant, awarded on Sep 30, 2023, will fund MGH's biomedical research efforts to study the genetic and epigenetic landscape of mucosal melanoma,...